Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms FluoroTau, 3H-THK5351, F-18 THK-5351 + [4] |
Target |
Action inhibitors |
Mechanism TAU inhibitors(Microtubule-associated protein tau inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC18H18FN3O2 |
InChIKeyDLVXFZWSPCOWSN-DHZJDKHOSA-N |
CAS Registry1707148-68-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neuroinflammation | Phase 2 | Taiwan Province | 01 Nov 2020 | |
Depressive Disorder, Major | Phase 2 | Taiwan Province | 23 Mar 2018 | |
Parkinson Disease | Phase 2 | Taiwan Province | 31 Jul 2017 | |
Supranuclear Palsy, Progressive | Phase 2 | Taiwan Province | 31 Jul 2017 | |
Alzheimer Disease | Phase 2 | United States | 11 Jan 2016 | |
Dementia | Phase 2 | Taiwan Province | 04 Jan 2016 | |
Mild cognitive disorder | Phase 2 | Taiwan Province | 04 Jan 2016 | |
Plaque, Amyloid | Phase 2 | Taiwan Province | 04 Jan 2016 | |
Stroke | Phase 2 | Taiwan Province | 04 Jan 2016 |
Phase 2 | 17 | Lumbar Puncture (optional)+18F-THK-5351 (Cognitive Impairment) | yedekqpxmw(tqzfgeffmq) = znydvyzbbh drxdgzmjco (vdflmjkied, ejyazjipvj - wjsnsgcrja) View more | - | 19 Nov 2018 | ||
Lumbar Puncture (optional)+18F-THK-5351 (No Cognitive Impairment) | yedekqpxmw(tqzfgeffmq) = bvfycnycnk drxdgzmjco (vdflmjkied, asbugakqie - dnnthxfmcw) View more | ||||||
Phase 1 | - | 12 | fbphkqclxc(qohgusdnny) = hyjazyojqj rnqeolygzg (dlxqvivccq ) | - | 01 Sep 2017 |